[go: up one dir, main page]

DK1682545T3 - Imidazopyridinsubstituerede tropanderivater med CCR5 receptorantagonistaktivitet til behandling af HIV og inflammation - Google Patents

Imidazopyridinsubstituerede tropanderivater med CCR5 receptorantagonistaktivitet til behandling af HIV og inflammation

Info

Publication number
DK1682545T3
DK1682545T3 DK04769496T DK04769496T DK1682545T3 DK 1682545 T3 DK1682545 T3 DK 1682545T3 DK 04769496 T DK04769496 T DK 04769496T DK 04769496 T DK04769496 T DK 04769496T DK 1682545 T3 DK1682545 T3 DK 1682545T3
Authority
DK
Denmark
Prior art keywords
imidazopyridine
hiv
inflammation
treatment
receptor antagonist
Prior art date
Application number
DK04769496T
Other languages
Danish (da)
English (en)
Inventor
Paul Anthony Stupple
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0323236.0A external-priority patent/GB0323236D0/en
Priority claimed from GB0325020A external-priority patent/GB0325020D0/en
Priority claimed from GB0418566A external-priority patent/GB0418566D0/en
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK1682545T3 publication Critical patent/DK1682545T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
DK04769496T 2003-10-03 2004-09-28 Imidazopyridinsubstituerede tropanderivater med CCR5 receptorantagonistaktivitet til behandling af HIV og inflammation DK1682545T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0323236.0A GB0323236D0 (en) 2003-10-03 2003-10-03 Chemical compounds
GB0325020A GB0325020D0 (en) 2003-10-27 2003-10-27 Chemical compounds
GB0418566A GB0418566D0 (en) 2004-08-19 2004-08-19 Tropane derivatives
PCT/IB2004/003153 WO2005033107A1 (fr) 2003-10-03 2004-09-28 Derives de tropane a substitution imidazopyridine en tant qu'antagonistes des recepteurs ccr5 pour le traitement du vih et de l'inflammation

Publications (1)

Publication Number Publication Date
DK1682545T3 true DK1682545T3 (da) 2008-03-17

Family

ID=34426592

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04769496T DK1682545T3 (da) 2003-10-03 2004-09-28 Imidazopyridinsubstituerede tropanderivater med CCR5 receptorantagonistaktivitet til behandling af HIV og inflammation

Country Status (35)

Country Link
US (2) US7309790B2 (fr)
EP (1) EP1682545B1 (fr)
JP (1) JP4874107B2 (fr)
KR (1) KR100777885B1 (fr)
AP (1) AP2174A (fr)
AR (1) AR045856A1 (fr)
AT (1) ATE380813T1 (fr)
AU (1) AU2004278158B2 (fr)
BR (1) BRPI0414862A (fr)
CA (1) CA2540834C (fr)
CY (1) CY1107281T1 (fr)
DE (1) DE602004010708T2 (fr)
DK (1) DK1682545T3 (fr)
EA (1) EA009941B1 (fr)
EC (1) ECSP066475A (fr)
ES (1) ES2295924T3 (fr)
GE (1) GEP20084417B (fr)
HN (1) HN2004000383A (fr)
HR (1) HRP20080052T3 (fr)
IL (1) IL174208A0 (fr)
MA (1) MA28080A1 (fr)
MX (1) MXPA06003749A (fr)
MY (1) MY137609A (fr)
NO (1) NO20061978L (fr)
NZ (1) NZ545837A (fr)
OA (1) OA13266A (fr)
PA (1) PA8614301A1 (fr)
PE (1) PE20050961A1 (fr)
PL (1) PL1682545T3 (fr)
PT (1) PT1682545E (fr)
RS (1) RS20060198A (fr)
SI (1) SI1682545T1 (fr)
TW (1) TWI280244B (fr)
UY (1) UY28546A1 (fr)
WO (1) WO2005033107A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7122542B2 (en) 2003-07-30 2006-10-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
RU2485106C2 (ru) 2005-06-08 2013-06-20 Райджел Фамэсьютикэлз, Инк. Соединения, проявляющие активность в отношении jak-киназы (варианты), способ лечения заболеваний, опосредованных jak-киназой, способ ингибирования активности jak-киназы (варианты), фармацевтическая композиция на основе указанных соединений
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
ES2553805T3 (es) 2006-04-05 2015-12-11 Opko Health, Inc. Formulaciones farmacéuticas que comprenden sales de (5S,8S)-8-[{(1R)-1-(3,5-bis-(trifluorometil)fenil]-etoxi}-metil]-8-fenil-1,7-diazaespiro[4.5]decan-2-ona y su utilización médica
WO2008030853A2 (fr) * 2006-09-06 2008-03-13 Incyte Corporation Thérapie de combinaison contre l'infection par le virus de l'immunodéficience humaine
CA2673125C (fr) 2006-10-19 2015-04-21 Rigel Pharmaceuticals, Inc. Compositions et procedes d'inhibition de la voie jak
US20090325936A1 (en) * 2006-12-20 2009-12-31 Bilodeau Mark T Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
PE20081891A1 (es) * 2007-03-22 2008-12-27 Opko Health Inc Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
SI2074120T1 (sl) * 2007-10-25 2010-06-30 Exelixis Inc Tropan spojine
HRP20170317T1 (hr) 2008-02-15 2017-04-21 Rigel Pharmaceuticals, Inc. Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza
PT2323993E (pt) 2008-04-16 2015-10-12 Portola Pharm Inc 2,6-diamino-pirimidina-5-il-carboxamidas como inibidores de quinasses syk ou jak
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8258144B2 (en) 2008-04-22 2012-09-04 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
CN105503870A (zh) 2009-08-14 2016-04-20 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂
PE20130529A1 (es) 2010-04-02 2013-05-14 Phivco 1 Llc Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico
EP2975027A1 (fr) 2010-11-01 2016-01-20 Portola Pharmaceuticals, Inc. Nicotinamides comme modulateurs de la kinase jak
EP2741777B1 (fr) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Procédés et compositions pharmaceutiques pour le traitement de l'hypertension pulmonaire
US8877760B2 (en) 2011-11-23 2014-11-04 Portola Pharmaceuticals, Inc. Substituted pyrazine-2-carboxamide kinase inhibitors
EP2903970A4 (fr) 2012-10-08 2016-11-30 Portola Pharm Inc Inhibiteurs substitués de pyrimidinyl kinase
AU2014326601B2 (en) * 2013-09-25 2018-01-18 SpecGx LLC Preparation of radioiodinated 3-fluoropropyl-nor-beta-CIT
GB201321748D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
WO2023192360A1 (fr) * 2022-03-31 2023-10-05 Incelldx, Inc. Méthodes de traitement d'un sujet pour une maladie de lyme post-traitement (ptld) et compositions destinées à être utilisées dans celles-ci
WO2023192361A1 (fr) * 2022-03-31 2023-10-05 Incelldx, Inc. Procédés de traitement d'un sujet pour la fibromyalgie et compositions destinées à être utilisées dans ceux-ci

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JP2899418B2 (ja) 1994-04-19 1999-06-02 ノイロサーチ アクティーゼルスカブ トロパン誘導体、それらの製造及び用途
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
ZA971525B (en) 1996-02-22 1997-10-21 Neurosearch As Tropane derivatives, their preparation and use.
WO2000035298A1 (fr) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing-gum contenant des agents medicamenteux actifs
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
ES2215129T3 (es) 2000-05-26 2004-10-01 Pfizer Inc. Derivados de triazolil tropano como modulares de ccr5.
US6855724B2 (en) * 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
OA12798A (en) * 2002-04-08 2006-07-10 Pfizer Tropane derivatives as CCR5 modulators.

Also Published As

Publication number Publication date
RS20060198A (sr) 2008-09-29
NZ545837A (en) 2009-12-24
JP4874107B2 (ja) 2012-02-15
AP2006003580A0 (en) 2006-04-30
CA2540834C (fr) 2010-06-22
IL174208A0 (en) 2006-08-01
HRP20080052T3 (hr) 2008-02-29
JP2007507483A (ja) 2007-03-29
CY1107281T1 (el) 2012-11-21
ECSP066475A (es) 2006-10-10
PT1682545E (pt) 2008-02-11
AU2004278158B2 (en) 2009-08-13
WO2005033107A1 (fr) 2005-04-14
ATE380813T1 (de) 2007-12-15
ES2295924T3 (es) 2008-04-16
EP1682545A1 (fr) 2006-07-26
PL1682545T3 (pl) 2008-04-30
EP1682545B1 (fr) 2007-12-12
OA13266A (en) 2007-01-31
KR100777885B1 (ko) 2007-11-28
UY28546A1 (es) 2005-05-31
NO20061978L (no) 2006-07-03
PA8614301A1 (es) 2005-05-10
TWI280244B (en) 2007-05-01
AR045856A1 (es) 2005-11-16
TW200519112A (en) 2005-06-16
PE20050961A1 (es) 2005-11-29
BRPI0414862A (pt) 2006-11-28
EA200600480A1 (ru) 2006-08-25
HN2004000383A (es) 2008-10-14
US7309790B2 (en) 2007-12-18
GEP20084417B (en) 2008-07-10
SI1682545T1 (sl) 2008-04-30
MA28080A1 (fr) 2006-08-01
DE602004010708D1 (de) 2008-01-24
MXPA06003749A (es) 2006-06-14
EA009941B1 (ru) 2008-04-28
US20050131011A1 (en) 2005-06-16
US20080045563A1 (en) 2008-02-21
CA2540834A1 (fr) 2005-04-14
US7790740B2 (en) 2010-09-07
AU2004278158A1 (en) 2005-04-14
MY137609A (en) 2009-02-27
DE602004010708T2 (de) 2008-12-04
KR20060070571A (ko) 2006-06-23
AP2174A (en) 2010-11-20

Similar Documents

Publication Publication Date Title
DK1682545T3 (da) Imidazopyridinsubstituerede tropanderivater med CCR5 receptorantagonistaktivitet til behandling af HIV og inflammation
DK2069342T3 (da) Derivater af 2-aryl-6-phenyl-imidazol[1,2-A]pyridiner, fremstilling og terapeutisk anvendelse deraf
DK1438298T3 (da) Piperazin-derivater med CCR1 receptor-antagonist-aktivitet
DK1583763T3 (da) Benzoazolylpiperazinderivater med VR1-antagonistaktivitet
DK1478339T3 (da) Farmaceutiske formuleringer af antineoplastiske midler, specielt temozolomid, fremgangsmåder til fremstilling og anvendelse heraf
DK1981889T3 (da) Cytotoksiske midler, der omfatter nye tomaymycin-derivater, og terapeutisk anvendelse deraf
IS2847B (is) Bífenýl afleiður með beta2 adrenerga viðtakaverkandi og múskarín viðtakaandverkandi virkni
DK1805312T3 (da) Fremgangsmåder og midler til fremstilling af hyaluronan
DK1578755T3 (da) Phosphonooxyguinalinderivater og deres farmaceutiske anvendelse
DK2046791T3 (da) Ureaderivater af tropan, fremstilling deraf og terepeutisk anvendelse deraf
EP1826209A4 (fr) Derives de nitromethylene et leur utilisation
NO20052739D0 (no) CCR5-antagonister som medikamenter
EP1720545A4 (fr) Heterocycles d'azote bicycliques et ponts
DK1537096T3 (da) Derivater af dioxan-2-alkylcarbamater, fremstilling og terapeutisk anvendelse heraf
DK1373256T3 (da) CCR5-antagonister, der er nyttige til behandling af AIDS
DK1922309T3 (da) N-phenyl-2-pyrimidin-aminderivater og fremgangsmåde til fremstillingen deraf
DK1487828T3 (da) Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme
DK2059508T3 (da) 5,6-bisaryl-2-pyridin-carboxamidderivater, fremstilling deraf og terapeutisk anvendelse deraf som urotensin II-receptorantagonister
DK1808446T3 (da) IL-18-receptor-antagonist og farmaceutisk sammensætning indeholdende antagonisten
NO20044330L (no) Heterosykliske amider med alfa-4 intergrin-antagonistaktivitet
DK1773796T3 (da) Oxopiperidinderivater, fremstilling deraf samt terapeutisk anvendelse deraf
EP1740120A4 (fr) Compositions de naltrexone, à action longue durée et méthode d'utilisation
PL1751175T3 (pl) Antagoniści receptora IL-1, kompozycje i sposoby leczenia
DK1594859T3 (da) Indazolamider med analgetisk aktivitet
DK1773829T3 (da) Aminotropanderivater, fremstilling og terapeutiske anvendelser heraf